Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.
  • Home
  • About Us
    • Management Team
    • Board of Directors
  • Products in Development
    • TO-2061
  • Investors
    • Press Releases
    • Events & Presentations
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Stock Information
      • Historic Stock Lookup
    • Analysts
    • Shareholder Tools
      • Shareholder Briefcase
      • Email Alerts
  • Careers
  • Contact
 

For more information, please click here »

News & Events

    Monday, May 14, 2012

    Transcept Pharmaceuticals Reports First Quarter 2012 Financial Results

    Wednesday, May 9, 2012

    Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences

    Monday, May 7, 2012

    Transcept Pharmaceuticals to Report First Quarter 2012 Financial Results and Host Conference Call on May 14, 2012

    Thursday, April 26, 2012

    Transcept Prices Public Offering of Common Stock

In Development

Transcept is developing TO-2061, a low dose form of ondansetron, as an adjunctive therapy in adult patients with obsessive compulsive disorder (OCD) not adequately responsive to currently approved OCD medication.

Click here for more information about TO-2061

Copyright © 2012  |  
Sitemap  |  Contact Us